<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The expression of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>/Testis (CT) antigens in some <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and restricted expression in <z:mpath ids='MPATH_458'>normal</z:mpath> tissue make CT antigens attractive vaccine targets </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the expression of MAGE-A3, PLAC1, GAGE, and CTAG2 in a series of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>CT <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was determined via quantitative PCR on paired <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> tissue samples from 82 CRC patients </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, plasma antibody titers specific to MAGE-A3, PLAC1, GAGE, and CTAG2 were determined via ELISA </plain></SENT>
<SENT sid="4" pm="."><plain>Tissue expression of MAGE-A3 was assessed via a standard IHC protocol </plain></SENT>
<SENT sid="5" pm="."><plain>The Student's t-test was used for statistical analysis (significance p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> expression of MAGE-A3, CTAG2, and GAGE was compared to the levels of expression in testis </plain></SENT>
<SENT sid="7" pm="."><plain>The percentage of samples that had a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vs. testis expression ratio above 0.1% was: MAGE-A3 (28%) and CTAG2 (17%) but no <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> presented GAGE expression levels above 0.1% </plain></SENT>
<SENT sid="8" pm="."><plain>The expression levels of PLAC1 in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were compared to the levels in placenta, and in 12.8% of the samples analyzed, these levels were above 0.1% </plain></SENT>
<SENT sid="9" pm="."><plain>Sero-reactivity specific for MAGE-A genes and PLAC1 was noted in 2.4% and 2.6% of patients, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>MAGE-A3 and PLAC1 may hold promise as vaccine targets for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Further study is warranted </plain></SENT>
</text></document>